Attached files
file | filename |
---|---|
10-Q - AIM ImmunoTech Inc. | v192725_10q.htm |
EX-10.3 - AIM ImmunoTech Inc. | v192725_ex10-3.htm |
EX-31.2 - AIM ImmunoTech Inc. | v192725_ex31-2.htm |
EX-10.1 - AIM ImmunoTech Inc. | v192725_ex10-1.htm |
EX-10.2 - AIM ImmunoTech Inc. | v192725_ex10-2.htm |
EX-31.1 - AIM ImmunoTech Inc. | v192725_ex31-1.htm |
EX-32.1 - AIM ImmunoTech Inc. | v192725_ex32-1.htm |
EX-10.4 - AIM ImmunoTech Inc. | v192725_ex10-4.htm |
EXHIBIT
32.2
CERTIFICATION
PURSUANT TO
SECTION
906 OF THE
SARBANES-OXLEY
ACT OF 2002
In
connection with the Quarterly Report of Hemispherx Biopharma, Inc. (the
“Company”) on Form 10-Q for the fiscal quarter ended June 30, 2010 as filed with
the Securities and Exchange Commission on the date hereof (the “Report”), I,
Charles T.
Bernhardt, Chief Financial Officer of the Company, certify, pursuant to
18 U.S.C. § 1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002,
that:
(1) The Report fully complies with the
requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934;
and
(2) The information contained in the
Report fairly presents, in all material respects, the financial condition and
result of operations of the Company.
Date:
August 6, 2010
/s/ Charles T. Bernhardt
|
|
Charles
T. Bernhardt, CPA
|
|
Chief
Financial Officer
|
1